MSBase Registry
@MSBase_Registry
Followers
745
Following
301
Media
35
Statuses
144
MSBase is an international real-world Neuroimmunology registry open to all practicing neurologists and their healthcare teams.
Joined September 2014
RT @darshi_r: Fantastic presentation from @Benjamin_Trewin regarding his data on optimal therapeutic dosing of corticosteroids at #MOGAD….
0
10
0
RT @ECTRIMS: #ECTRIMS2024 | Welcome to the 1st day of the 40th Congress of ECTRIMS! Thank YOU for being a vital part of this journey. 📽️ Wa….
0
4
0
RT @ECTRIMS: 🚨 LIVE in 15 minutes! Join Scientific Session 1 on the revised diagnostic criteria w/ MS experts, incl. @xmontalban, @Marcello….
0
6
0
MSBase is 20 years old!! and holds >110,000 patient records. Dedicated clinicians all over the world contributes data with >110 papers, many that have changed clinical practice. We are so grateful to all the supporters of our mission to improve the lives of people with #MS.
0
2
13
RT @drmankad: Your roadmap for Autoimmune Encephalitis. A useful slide being shared from our UK Childhood Neuroinflammatory Disorders meeti….
0
202
0
RT @JNNP_BMJ: 📢🔥Take note! Data from the massive @MSBase_Registry dataset shows that secondary and primary progressive MS disease differ in….
0
3
0
RT @anneke_vdw: Fantastic catching up with friends &colleagues from the #BigMS data registries. Collectively, we manage ~300,000 patient re….
0
5
0
Festive greetings and a joyous Christmas from the MSBase Management team, to our amazing MSBase Ops Team, SLG committees, Board and valued Members - wishing you all a safe and happy holiday season.
0
1
7
RT @MonashNeurosci: New published data @MonashCCS @Alfred_Research @HelmutButz @MSBase_Registry to support clinical decision making for pat….
monash.edu
0
2
0
RT @Brandon_Beaber: Is HSCT really that good? This analysis at #ECTRIMS2022 (unrandomized) found HSCT is better than gilenya but similar i….
0
11
0
RT @KlausSchmierer: 🌷Late breaking news at #ECTRIMS2022 @Iamsterdam Surprising or not? Propensity matched study of #HSCT versus #Natalizuma….
0
10
0
RT @vjokubaitis: Izanne Roos presenting a non-inferiority study of ocrelizumab and rituximab on behalf of the @MSBase_Registry and the Dani….
0
3
0
RT @drbarrysinger: Kalincik @MSBase_Registry study: Propensity-matched #progressive #MS patients treated with AHSCT or natalizumab. No diff….
0
3
0
RT @vjokubaitis: Visiting the hard working team at the @MSBase_Registry booth at #ECTRIMS2022 thank you to Charlotte Sartori, Pam Farr, Rei….
0
1
0
RT @drruthdobson: Made it into the pregnancy session in time for a really relevant talk by Annika Anderson - low transfer of CD20 molecules….
0
2
0
RT @UKMSRegister: Excellent talk by @annalauralerede from at #ECTRIMS2022 presenting on the different ways MS can progress over time (usin….
0
2
0
RT @EllenMowryMD: Dr. Nicole Bou Rjeily starting a great presentation at ECTRIMS. Strong scientist and future neurologist!. @IntNatlWiMS @E….
0
4
0
Chao Zhu representing @MSBase_Registry data @ECTRIMS #DMT efficacy. Congratulations to all MSBase investigators involved!
0
2
7
RT @drruthdobson: In prospectively reported cases, no increased risk of spontaneous pregnancy loss, preterm birth, ectopic pregnancy. Rate….
0
5
0